Latest news with #animalhealth
Globe and Mail
a day ago
- Business
- Globe and Mail
Beat the S&P 500 With This Cash-Gushing Dividend Stock
You don't need to uncover the next big artificial intelligence stock to outperform the broader stock market. Sometimes, consistent and profitable growth is all you need to achieve outsize investment returns. Zoetis (NYSE: ZTS) is an animal healthcare company that split off from Pfizer in 2013. The stock has beaten the S&P 500 ever since, and now may be as good an opportunity as any to buy the stock. Here is why Zoetis is a compelling buy today, and why investors can continue to expect outstanding investment returns over the coming years. A powerhouse product portfolio with many winners Innovation is at the core of the pharmaceutical business, where companies invest substantial resources to develop and obtain regulatory approval for drugs and therapies. Once approved, their patents essentially block out competition for years. The catch is that drug development often fails, so the winners need to compensate for the failures, too. Size and deep pockets are advantages here, and Zoetis sits at the top of the mountain in animal health. The company develops and sells devices and drugs for treating pets and livestock, including cats and dogs, cattle, fish, swine, and poultry. The company expects 2025 sales to exceed $9.2 billion, driven by a portfolio of approximately 300 product lines, including 17 blockbusters that generated at least $100 million in sales last year. Its diversity translates to stable revenue streams. Zoetis' annual sales have continually set new records every year since the company began trading over a decade ago. Zoetis grows and gushes cash, a lucrative combination Zoetis is a highly profitable enterprise, converting roughly $0.25 of every revenue dollar into free cash flow. Having billions of dollars in annual cash profits enables Zoetis to hit the investing trifecta for great stocks: Doing all these things simultaneously is why the stock has performed as well as it has. Data by YCharts. Importantly, this should continue for the foreseeable future. Studies have shown that millennial and Gen Z Americans are driving growth in pet expenditures and ownership rates. Pet owners form emotional bonds with companion animals, which will likely translate to a growing market opportunity for Zoetis, as well as pricing power and spending resiliency through economic cycles. Additionally, livestock remains a long-term growth opportunity. A growing global population will consume more protein, and Zoetis' worldwide footprint should position it for growth in emerging markets, where much of that growth is likely to occur. The stock's valuation isn't usually this attractive You would look at Zoetis and its price-to-earnings (P/E) ratio of 30 and assume the stock is expensive. Ironically, it rarely becomes this cheap. Analysts estimate the company will grow earnings by an average of around 10% annually over the long term. Most stocks with healthy but unspectacular growth don't trade at such valuations. However, Zoetis' business has been such a consistent performer that investors value the stock for its safety. No stock is a sure bet, but you can feel pretty confident about buying and holding this one. Data by YCharts. Ideally, the stock's valuation will become even cheaper, but as you can see, that's a risk because it hasn't fallen much from these levels in over a decade's worth of history. If Zoetis continues to perform as it has, the stock has a good chance of at least maintaining its current P/E ratio, meaning growth and dividends will drive the stock's returns. Investors can realistically expect somewhere around 11% annualized returns, driven by earnings growth and a rising dividend that yields 1.2% today. It's not explosive, but solid, steady returns can outrun the broader market over the long term. Should you invest $1,000 in Zoetis right now? Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Entrepreneur
3 days ago
- Business
- Entrepreneur
How This Entrepreneur Is Disrupting Pet Health
When Andrew Hamilton set out to launch his vision went far beyond building a convenient online pharmacy. For Hamilton, a seasoned entrepreneur with a passion for improving access to veterinary care, it was personal. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media. When Andrew Hamilton set out to launch his vision went far beyond building a convenient online pharmacy. For Hamilton, a seasoned entrepreneur with a passion for improving access to veterinary care, it was personal. His own experiences navigating the complexities of pet health inspired him to create not just a platform — but also a solution. The first solution came in the form of ToltraMax, an oral toltrazuril-based treatment developed by Hamilton and his team to address one of the most persistent yet overlooked challenges in animal health: coccidiosis. Coccidiosis, caused by microscopic parasites called Eimeria, is a common intestinal issue that affects pets, livestock, and companion animals alike. For breeders, veterinarians, and everyday pet owners, managing outbreaks of this parasite can be costly, time-consuming, and stressful. Hamilton saw a clear need for a more practical, widely applicable treatment option — one that was effective, accessible, and simple to administer. That's how ToltraMax was born. Innovating Where It Matters Most Unlike many entrepreneurs who focus solely on platform technology, Hamilton dove into product development. Together with his team, he formulated ToltraMax as a high-concentration (10%) toltrazuril oral solution designed for companion animal use — including dogs, cats, horses and other non foodchain animals. The goal wasn't to compete with pharmaceutical giants on brand recognition. It was to create a tool that addressed real problems in the field, offering animal caretakers a reliable option to support intestinal health related to coccidia. ToltraMax is currently available through and where it has found a strong foothold among pet and equine caretakers. However, its broader applications make it a natural fit for the direct-to-consumer model that Hamilton envisions for plugins and affilate programs. Building the Infrastructure for Accessible Care set to launch later this year, represents Hamilton's larger vision: an integrated platform where pet owners can access trusted medications, telehealth support, and educational resources in one place. "We created ToltraMax because there was a treatment gap in the market," Hamilton explains. "But creating the product is only half the battle. The real challenge is making sure people can actually get it when they need it quickly." That challenge is exactly what is working to address. With additional generic drug applications currently pending, is preparing to expand its offerings and close more of these critical gaps in animal healthcare. Earlier this year, Hamilton secured $21 million in funding from Palehorse Capital to support development and expansion. The investment reflects growing recognition of the need for affordable, accessible veterinary solutions — especially as pet ownership rises and traditional access points remain limited. More Than a Product: A Founder's Mission While ToltraMax serves as flagship offering, Hamilton sees it as the first step in a much larger journey. By controlling both the product development and distribution channels, he aims to eliminate common barriers pet owners face, from high medication costs to lack of availability. won't replace vet visits — a point Hamilton emphasizes often. Instead, it will work hand in hand with licensed veterinarians to provide a trusted pathway for pet owners to access products like ToltraMax, while encouraging responsible use through teleconsultations and professional guidance. "Our focus is on supporting pet owners and veterinarians with better tools," Hamilton says. "ToltraMax reflects that philosophy — it's practical, effective, and designed with real-world challenges in mind." What's Next As the platform prepares for launch, Hamilton remains focused on scaling responsibly, ensuring that both the product and the platform maintain the high standards he set out to establish. Hamilton's approach offers a compelling case study in vertical integration: identify a problem, create a solution, and build the infrastructure to deliver it. In a crowded digital health market, his model of product-plus-platform stands out. For pet owners and veterinary professionals, it's a welcome sign of things to come.
Yahoo
3 days ago
- Business
- Yahoo
United States Veterinary Education Market Report 2025: Regional Insights, Competition, Forecast & Opportunities, 2020-2030 - How Certificate Programs Are Transforming the Landscape
The U.S. Veterinary Education Market is growing due to increased demand for veterinary professionals, driven by rising pet ownership and a heightened focus on animal health. Opportunities include enhancing curricula with innovative tech and adding certificate programs. Challenges include a shortage of qualified educators. U.S. Veterinary Education Market Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "United States Veterinary Education Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The United States Veterinary Education Market was valued at USD 0.76 Billion in 2024, and is expected to reach USD 1.19 Billion by 2030, rising at a CAGR of 7.71% The market is experiencing notable growth due to evolving industry needs and a rising demand for skilled veterinary professionals. Educational institutions are enhancing curricula by integrating evidence-based methodologies and innovative learning technologies. Increased pet ownership, heightened awareness of animal welfare, and the expanding role of veterinarians in public health and food safety are driving the need for veterinary education. Additionally, the emergence of veterinary subspecialties such as oncology and cardiology has spurred the development of advanced training programs. Strategic collaborations among veterinary schools, industry stakeholders, and government entities are fostering an enriched educational ecosystem that supports structured learning and financial assistance for students. Rising Demand for Veterinary Professionals The growing need for veterinary professionals is a major driver of the United States Veterinary Education Market. According to the U.S. Bureau of Labor Statistics, veterinary employment is expected to increase by 19% between 2022 and 2032, a rate significantly higher than the average across all occupations. This surge is largely fueled by the rise in pet ownership, with the American Veterinary Medical Association reporting over 85 million U.S. households owning pets in 2023. As companion animal populations expand, so does the requirement for veterinary services, including preventive care and medical treatment. The livestock industry is also contributing to this demand by prioritizing animal health to ensure food safety and regulatory compliance. The USDA has noted an uptick in animal production practices requiring veterinary oversight. Furthermore, the profession's growing involvement in public health, particularly in managing zoonotic diseases, reinforces the critical role veterinarians play beyond traditional clinical settings. Shortage of Qualified Faculty and Mentors A significant challenge confronting the United States Veterinary Education Market is the shortage of qualified faculty and mentors. As demand for veterinary professionals rises, institutions are finding it difficult to recruit and retain educators with both academic expertise and clinical experience. One major reason is the more competitive salaries offered in private practice and industry roles, making academic positions less appealing. This shortage reduces the capacity of veterinary programs to admit students, limiting the pipeline of future veterinarians. It also affects the quality of instruction, particularly during hands-on clinical rotations that are essential for practical learning. Specialized disciplines like surgery and internal medicine are especially impacted, where expert mentorship is vital. Without sufficient faculty support, student training and overall educational standards may suffer. Rise of Certificate Programs The growing adoption of certificate programs is a key trend reshaping the United States Veterinary Education Market. These programs offer targeted, flexible training in specific areas such as animal nutrition, infectious diseases, anesthesiology, and clinical techniques, without the need for full-degree commitments. Designed for both practicing professionals and students, these certifications allow rapid skill enhancement in a cost-effective manner. They serve as a practical continuing education tool, keeping veterinary practitioners abreast of current advancements and compliance requirements. With the veterinary sector demanding more specialized expertise, certificate programs help improve patient outcomes and expand career opportunities. Their modular nature and industry relevance make them a valuable addition to traditional veterinary education pathways. Key Attributes: Report Attribute Details No. of Pages 86 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $0.76 Billion Forecasted Market Value (USD) by 2030 $1.19 Billion Compound Annual Growth Rate 7.7% Regions Covered United States Report Scope Key Market Players: University of California - Davis Cornell University Auburn University Tuskegee University University of Arizona Midwestern University University of Florida University of Georgia University of Illinois Purdue University United States Veterinary Education Market, By Course: Graduate Courses Post-graduate Courses Standalone Courses United States Veterinary Education Market, By Specialty: Veterinary Surgery Veterinary Medicine Veterinary Nursing Animal Grooming Other Specialties United States Veterinary Education Market, By Institution: Public Private United States Veterinary Education Market, By Delivery Mode: Classroom based Courses E-Learning United States Veterinary Education Market, By Region: North-East Mid-West West South For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Veterinary Education Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Bloomberg
24-05-2025
- Health
- Bloomberg
Record £1.23bn Paid Out in Pet Insurance Claims in 2024
A record £1.23 billion was paid out in pet insurance claims in 2024, helping households cover the cost of veterinary treatment for unwell and injured animals, the Association of British Insurers (ABI) has said. Dogs led the pack, making up £933 million in claims, followed by cats at £232 million, and £61 million for other pets.
The Independent
23-05-2025
- Health
- The Independent
Record £1.23bn paid out in pet insurance claims in 2024, says ABI
A record £1.23 billion was paid out in pet insurance claims in 2024, helping households cover the cost of veterinary treatment for unwell and injured animals, the Association of British Insurers (ABI) has said. Dogs led the pack, making up £933 million in claims, followed by cats at £232 million, and £61 million for other pets. The total for 2024 was 4% higher than 2023 and marks the third year in a row that total payouts by ABI members have surpassed £1 billion. The ABI said members received 1.8 million claims last year – equating to around 4,900 claims per day typically. Its data also indicates that a record 4.6 million pet owners took out insurance – a 3% increase since 2023 and a third (33%) higher than before the coronavirus pandemic in 2019. Many people acquired new pets during the coronavirus lockdowns. The average claim cost is £685, the ABI said, but some costs can be much higher. The price of treatment for elbow dysplasia, a common cause of forelimb lameness in young, large and giant breed dogs, can cost over £50,000, the body said. The average cost of care needed when a pet eats something they should not, whether it is food which is poisonous to them or a small household item, is around £4,000, the ABI said. Jonathan Purvis, senior policy adviser, general insurance at the ABI said: 'You can't pull a rabbit out the hat when it comes to paying for veterinary bills, so it's promising to see more people making sensible choices to protect themselves and their pets financially. ' Insurance provides peace of mind that costs will be covered if your pet is ill or injured.'
